Rhythm Pharmaceuticals

Rhythm Pharmaceuticals

Yahoo Finance • 21 days ago

Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal

Billionaire Stanley Druckenmiller, who runs the Duquesne Family Office hedge fund, has been loading up on healthcare stocks. A year ago, healthcare stocks represented almost 22% of the fund's portfolio. Today, that representation is up to... Full story

Yahoo Finance • 23 days ago

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are currently the leaders in the weight loss market. Their medicines have proved highly effective and generate billions in annual sales. However, drugs such as Wegovy and Zepbound are inte... Full story

Yahoo Finance • last month

Rhythm Pharmaceuticals GAAP EPS of -$0.73 beats by $0.09, revenue of $71.26M beats by $3.6M

* Rhythm Pharmaceuticals press release [https://seekingalpha.com/pr/20605381-rhythm-pharmaceuticals-reports-second-quarter-2026-financial-results-and-business-update] (RYTM [https://seekingalpha.com/symbol/RYTM]): Q2 GAAP EPS of -$0.73 b... Full story

Yahoo Finance • last month

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

-- U.S. launch of IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second quarter 2026 net product revenue from global sal... Full story

Yahoo Finance • 2 months ago

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties to sha... Full story

Yahoo Finance • 2 months ago

Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates

Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The "Oral Obesity Therapies Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Oral Obesity Therapies Market Global Report 2026 provides strategists, marketers, invest... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story

Yahoo Finance • 3 months ago

Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the best biotech stocks on this list. TheFly reported on June 16 that Canaccord analyst Whitney I... Full story

Yahoo Finance • 3 months ago

Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the most promising healthcare stocks according to Wall Street analysts. On June 13, Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) shared preliminary results from its ongoing Phase 2 trial o... Full story

Yahoo Finance • 3 months ago

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas inclu... Full story

Yahoo Finance • 3 months ago

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

-- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- -- Bivamelagon therapy achieved progressive reductions in BMI and hunger measures in patients (N=26) w... Full story

Yahoo Finance • 3 months ago

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures -- --... Full story

Yahoo Finance • 3 months ago

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story

Yahoo Finance • 4 months ago

Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday

Key Points The biotech was in the headlines recently after the FDA approved a new indication for its single commercialized drug. There might be more where that came from with Imcivree.10 stocks we like better than Rhythm Pharmaceuticals ›... Full story

Yahoo Finance • 5 months ago

Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) ranks 5th on this list. While Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) faces high cash burn, hedge fu... Full story

Yahoo Finance • 5 months ago

Rhythm Pharmaceuticals Announces Changes to Board of Directors

-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the l... Full story

Yahoo Finance • 6 months ago

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming... Full story

Yahoo Finance • 6 months ago

Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'

Rhythm Pharmaceuticals stock ultimately closed down Friday, though the FDA signed off on its drug, Imcivree, for a genetic form of obesity. Continue Reading... Full story

Yahoo Finance • 6 months ago

Stocks Fall on Spillover Effects from Iran War

The S&P 500 Index ($SPX) (SPY) today is down -0.88%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.59%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.22%.  March E-mini S&P futures (ESM26) are down -0.95%, and March E-mini... Full story

Yahoo Finance • 6 months ago

Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) is one of the most promising stocks under $100 to buy. On March 16, Rhythm Pharmaceuticals announced topline results from its global Phase 3 EMANATE trial, which evaluated the efficacy of setmelano... Full story